Anika Therapeutics Inc
(NAS:ANIK)
$
17.35
-0.2 (-1.14%)
Market Cap: 254.10 Mil
Enterprise Value: 219.27 Mil
PE Ratio: 0
PB Ratio: 1.42
GF Score: 70/100 Anika Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019 / 12:35PM GMT
Release Date Price:
$55.61
(+0.93%)
Jonathan Guskind;Executive Director
Healthcare Investment Banking,
Good morning. Before we get started, just a quick disclosure. Please note that all-important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.
Again, good morning, everyone. My name is Jonathan Guskind. I'm the Morgan Stanley health care investment banking team. It is my pleasure to have with me this morning Anika Therapeutics and their CEO, Joe Darling; and CFO, Sylvia Cheung. Why don't we just jump right into it?
Questions & Answers
Jonathan Guskind;Executive Director;Joseph G. Darling
Healthcare Investment Banking,;Anika Therapeutics, Inc. - CEO, President
Our first question. Joe, for those less familiar with Anika, can you provide a brief overview of the company?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot